Search

Your search keyword '"Mahmmod, Nofel"' showing total 199 results
Start Over Author "Mahmmod, Nofel"
199 results on '"Mahmmod, Nofel"'

1. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease

Author

van Bodegraven, Adriaan A., Fidder, Herma H., Hirdes, Meike M.C., Hoentjen, Frank, Jansen, Jeroen M., Mahmmod, Nofel, van der Meulen-de Jong, Andrea E., Ponsioen, Cyriel Y., van Schaik, Fiona D.M., van der Woude, C. Janneke, Wijnands, Anouk M., Penning de Vries, Bas B.L., Lutgens, Maurice W.M.D., Bakhshi, Zeinab, Al Bakir, Ibrahim, Beaugerie, Laurent, Bernstein, Charles N., Chang-ho Choi, Ryan, Coelho-Prabhu, Nayantara, Graham, Trevor A., Hart, Ailsa L., ten Hove, Joren R., Itzkowitz, Steven H., Kirchgesner, Julien, Mooiweer, Erik, Shaffer, Seth R., Shah, Shailja C., Elias, Sjoerd G., and Oldenburg, Bas

Published
2024
Full Text
View/download PDF

2. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease

Author

Mahmoud, Remi, Savelkoul, Edo H.J., Mares, Wout, Goetgebuer, Rogier, Witteman, Ben J.M., de Koning, Daan B., van Tuyl, Sebastiaan A.C., Minderhoud, Itta, Lutgens, Maurice W.M. D., Akol-Simsek, Dilek, van Schaik, Fiona D.M., Fidder, Herma H., Jansen, Jeroen M., van Boeckel, Petra G.A., Mahmmod, Nofel, Horjus-Talabur Horje, Carmen S., Römkens, Tessa E.H., Colombel, Jean-Frédéric, Hoentjen, Frank, Jharap, Bindia, and Oldenburg, Bas

Published
2023
Full Text
View/download PDF

4. Healthy Cotwins Share Gut Microbiome Signatures With Their Inflammatory Bowel Disease Twins and Unrelated Patients

Author

Oldenburg, Bas, van Wijk, Femke, Brand, Eelco C., Honkoop, Pieter, Jacobs, Rutger J., Ponsioen, Cyriel Y., de Boer, Nanne K.H., Alderlieste, Yasser A., van Herwaarden, Margot A., van Tuyl, Sebastiaan A.C., Lutgens, Maurice W., Janneke van der Woude, C., Mares, Wout G.M., de Koning, Daan B., Bosman, Joukje H., Vecht, Juda, de Schryver, Anneke M.P., van der Meulen-de Jong, Andrea E., Pierik, Marieke J., Boekema, Paul J., Verburg, Robert J., Jharap, Bindia, Willemsen, Gonneke, Boomsma, Dorret I., Jansen, Jeroen M., Stokkers, Pieter C.F., Hoentjen, Frank, Quispel, Rutger, Horjus Talabur Horje, Carmen S., van de Meeberg, Paul C., Mahmmod, Nofel, West, Rachel L., Willems, Marleen, Minderhoud, Itta M., Fidder, Herma H., van Schaik, Fiona D.M., Hirdes, Meike M.C., Boontje, Nynke A., Müskens, Bart L.M., Weersma, Rinse K., Romberg-Camps, Marielle J.L., Klaassen, Marjolein A.Y., Gacesa, Ranko, Vich Vila, Arnau, Ghosh, Hiren, de Zoete, Marcel R., Fu, Jingyuan, Wijmenga, Cisca, and Zhernakova, Alexandra

Published
2021
Full Text
View/download PDF

5. Methotrexate accumulation in target intestinal mucosa and white blood cells differs from non‐target red blood cells of patients with Crohn's disease.

Author

van de Meeberg, Maartje M., Sundaresan, Janani, Lin, Marry, Jansen, Gerrit, Struys, Eduard A., Fidder, Herma H., Oldenburg, Bas, Mares, Wout G. N., Mahmmod, Nofel, van Asseldonk, Dirk P., Rietdijk, Svend T., Nissen, Loes H. C., de Boer, Nanne K. H., Bouma, Gerd, Ćalasan, Maja Bulatović, and de Jonge, Robert

Subjects
CROHN'S disease, MONONUCLEAR leukocytes, DRUG monitoring, LEUCOCYTES, SKEWNESS (Probability theory), ERYTHROCYTES, INTESTINAL mucosa
Abstract

Background: Intracellular methotrexate polyglutamates (MTX‐PGs) concentrations are measurable in red blood cells (RBCs) during MTX treatment. MTX‐PG3 concentrations correlate with efficacy in patients with Crohn's disease (CD). Since RBCs are not involved in pathogenesis of CD and lack extended MTX metabolism, we determined MTX‐PGs accumulation in peripheral blood mononuclear cells (PBMCs: effector cells) and intestinal mucosa (target cells) and compared those with RBCs as a potential more precise biomarker. Methods: In a multicentre prospective cohort study, blood samples of patients with CD were collected during the first year of MTX therapy. Mucosal biopsies were obtained from non‐inflamed rectum and/or inflamed intestine. MTX‐PGs concentrations in mucosa, PBMCs and RBCs were measured by liquid chromatography–tandem mass spectrometry. Results: From 80 patients with CD, a total of 27 mucosal biopsies, 9 PBMC and 212 RBC samples were collected. From 12 weeks of MTX therapy onwards, MTX‐PG3 was the most predominant species (33%) in RBCs. In PBMCs, the distribution was skewed towards MTX‐PG1 (48%), which accounted for an 18 times higher concentration than in RBCs. Long‐chain MTX‐PGs were highly present in mucosa: 21% of MTX‐PGtotal was MTX‐PG5. MTX‐PG6 was measurable in all biopsies. Conclusions: MTX‐PG patterns differ between mucosa, PBMCs and RBCs of patients with CD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial

Author

Hart, Ailsa, Warusavitarne, Janindra, Van Bodegraven, Ad A., Brink, Menno A., Consten, Esther C.J., Van Wagensveld, Bart A., Rijk, Marno C.M., Crolla, Rogier M.P.H., Noomen, Casper G., Houdijk, Alexander P.J., Mallant, Rosalie C., Boom, Maarten, Marsman, Willem A., Stockmann, Hein B., De Groof, A. Jeroen, Bruin, Karlien, Maring, John, van Ditzhuijsen, Theo, Prins, Hubert, van den Brande, Jan, Kingma, Paul, van Geloven, Anna, de Boer, Nanne, van der Peet, Donald, Jansen, Jeroen, Gerhards, Michael, van der Woude, Janneke, Schouten, Ruud, Oldenburg, Bas, van Hillegersberg, Richard, West, Rachel, Mannaerts, Guido, Spanier, Marcel, Spillenaar Bilgen, Ernst Jan, Lieverse, Rob, van der Zaag, Edwin, Depla, Annekatrien, van de Laar, Arnold, Bolwerk, Clemens, Brouwer, Hans, Mahmmod, Nofel, Hazebroek, Eric, Vecht, Juda, Pierik, Robert, Dijkstra, Gerard, Hofker, Sijbrand, Uiterwaal, Tessa, Eijsbouts, Quirijn, Oostenbrug, Liekele, Sosef, Meindert, Cahen, Djuna, van der Werff, Sjoerd, Marinelli, Andreas, Peters, Job, Cense, Huib, Talstra, Nynke, Morar, Pritesh, Stevens, Toer W, Haasnoot, Maria L, D'Haens, Geert R, Buskens, Christianne J, de Groof, E Joline, Eshuis, Emma J, Gardenbroek, Tjibbe J, Mol, Bregje, Stokkers, Pieter C F, Bemelman, Willem A, and Ponsioen, Cyriel Y

Published
2020
Full Text
View/download PDF

8. Methotrexate accumulation in target intestinal mucosa and white blood cells differs from non-target red blood cells of patients with Crohn's disease

Author

Unit Opleiding MDL, Genetica Sectie Metabole Diagnostiek, MS MDL 1, Cancer, Infection & Immunity, van de Meeberg, Maartje M, Sundaresan, Janani, Lin, Marry, Jansen, Gerrit, Struys, Eduard A, Fidder, Herma H, Oldenburg, Bas, Mares, Wout G N, Mahmmod, Nofel, van Asseldonk, Dirk P, Rietdijk, Svend T, Nissen, Loes H C, de Boer, Nanne K H, Bouma, Gerd, Ćalasan, Maja Bulatović, de Jonge, Robert, On behalf on the Dutch Initiative on Crohn and Colitis (ICC), Unit Opleiding MDL, Genetica Sectie Metabole Diagnostiek, MS MDL 1, Cancer, Infection & Immunity, van de Meeberg, Maartje M, Sundaresan, Janani, Lin, Marry, Jansen, Gerrit, Struys, Eduard A, Fidder, Herma H, Oldenburg, Bas, Mares, Wout G N, Mahmmod, Nofel, van Asseldonk, Dirk P, Rietdijk, Svend T, Nissen, Loes H C, de Boer, Nanne K H, Bouma, Gerd, Ćalasan, Maja Bulatović, de Jonge, Robert, and On behalf on the Dutch Initiative on Crohn and Colitis (ICC)

Published
2024

10. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease

Author

Wijnands, Anouk M., primary, Penning de Vries, Bas B.L., additional, Lutgens, Maurice W.M.D., additional, Bakhshi, Zeinab, additional, Al Bakir, Ibrahim, additional, Beaugerie, Laurent, additional, Bernstein, Charles N., additional, Chang-ho Choi, Ryan, additional, Coelho-Prabhu, Nayantara, additional, Graham, Trevor A., additional, Hart, Ailsa L., additional, ten Hove, Joren R., additional, Itzkowitz, Steven H., additional, Kirchgesner, Julien, additional, Mooiweer, Erik, additional, Shaffer, Seth R., additional, Shah, Shailja C., additional, Elias, Sjoerd G., additional, Oldenburg, Bas, additional, van Bodegraven, Adriaan A., additional, Fidder, Herma H., additional, Hirdes, Meike M.C., additional, Hoentjen, Frank, additional, Jansen, Jeroen M., additional, Mahmmod, Nofel, additional, van der Meulen-de Jong, Andrea E., additional, Ponsioen, Cyriel Y., additional, van Schaik, Fiona D.M., additional, and van der Woude, C. Janneke, additional

Published
2024
Full Text
View/download PDF

11. High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease

Author

Shah, Shailja C., ten Hove, Joren R., Castaneda, Daniel, Palmela, Carolina, Mooiweer, Erik, Colombel, Jean-Frédéric, Harpaz, Noam, Ullman, Thomas A., van Bodegraven, Ad A., Jansen, Jeroen M., Mahmmod, Nofel, van der Meulen-de Jong, Andrea E., Ponsioen, Cyriel Y., van der Woude, Christine J., Oldenburg, Bas, Itzkowitz, Steven H., and Torres, Joana

Published
2018
Full Text
View/download PDF

12. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial

Author

Bruin, Karlien, Maring, John, van Ditzhuijsen, Theo, Prins, Hubert, van den Brande, Jan, Kingma, Paul, van Geloven, Anna, de Boer, Nanne, van der Peet, Donald, Jansen, Jeroen, Gerhards, Michael, van der Woude, Janneke, Schouten, Ruud, Oldenburg, Bas, van Hillegersberg, Richard, West, Rachel, Mannaerts, Guido, Spanier, Marcel, Spillenaar Bilgen, Ernst Jan, Lieverse, Rob, van der Zaag, Edwin, Depla, Annekatrien, van de Laar, Arnold, Bolwerk, Clemens, Brouwer, Hans, Mahmmod, Nofel, Hazebroek, Eric, Vecht, Juda, Pierik, Robert, Dijkstra, Gerard, Hofker, Sijbrand, Uiterwaal, Tessa, Eijsbouts, Quirijn, Oostenbrug, Liekele, Sosef, Meindert, Cahen, Djuna, van der Werff, Sjoerd, Marinelli, Andreas, Peters, Job, Cense, Huib, Talstra, Nynke, Morar, Pritesh, Ponsioen, Cyriel Y, de Groof, E Joline, Eshuis, Emma J, Gardenbroek, Tjibbe J, Bossuyt, Patrick M M, Hart, Ailsa, Warusavitarne, Janindra, Buskens, Christianne J, van Bodegraven, Ad A, Brink, Menno A, Consten, Esther C J, van Wagensveld, Bart A, Rijk, Marno C M, Crolla, Rogier M P H, Noomen, Casper G, Houdijk, Alexander P J, Mallant, Rosalie C, Boom, Maarten, Marsman, Willem A, Stockmann, Hein B, Mol, Bregje, de Groof, A Jeroen, Stokkers, Pieter C, D'Haens, Geert R, and Bemelman, Willem A

Published
2017
Full Text
View/download PDF

13. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial

Author

de Jong, Marin J, van der Meulen-de Jong, Andrea E, Romberg-Camps, Mariëlle J, Becx, Marco C, Maljaars, Jeroen P, Cilissen, Mia, van Bodegraven, Ad A, Mahmmod, Nofel, Markus, Tineke, Hameeteman, Wim M, Dijkstra, Gerard, Masclee, Ad A, Boonen, Annelies, Winkens, Bjorn, van Tubergen, Astrid, Jonkers, Daisy M, and Pierik, Marie J

Published
2017
Full Text
View/download PDF

14. Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.

Author

van de Meeberg, Maartje M., Fidder, Herma H., Oldenburg, Bas, Sundaresan, Janani, Struys, Eduard A., Montazeri, Nahid S. M., Mares, Wout G. N., Mahmmod, Nofel, van Asseldonk, Dirk P., Lutgens, Maurice W. M. D., Kuyvenhoven, Johan P., Rietdijk, Svend T., Nissen, Loes H. C., Koehestanie, Parweez, de Boer, Nanne K. H., de Jonge, Robert, Bouma, Gerd, Bulatović Ćalasan, Maja, van Schaik, Fiona, and van der Horst, Inge

Subjects
CROHN'S disease, DRUG monitoring, PATIENT monitoring, TERMINATION of treatment, METHOTREXATE
Abstract

Summary: Background: Therapeutic drug monitoring (TDM) has the potential to improve efficacy and diminish side effects. Measuring methotrexate‐polyglutamate (MTX‐PG) in erythrocytes might enable TDM for methotrexate in patients with Crohn's disease (CD). Aim: To investigate the relationship between MTX‐PGs and methotrexate drug survival, efficacy and toxicity Methods: In a multicentre prospective cohort study, patients with CD starting subcutaneous methotrexate without biologics were included and followed for 12 months. Primary outcome was subcutaneous methotrexate discontinuation or requirement for step‐up therapy. Secondary outcomes included faecal calprotectin (FCP), Harvey Bradshaw Index (HBI), hepatotoxicity and gastrointestinal intolerance. Erythrocyte MTX‐PGs were analysed at weeks 8, 12, 24 and 52 or upon treatment discontinuation. Results: We included 80 patients with CD (mean age 55 ± 13y, 35% male) with a median FCP of 268 μg/g (IQR 73–480). After the 12‐month visit, 21 patients (26%) were still on subcutaneous methotrexate monotherapy. Twenty‐one patients stopped because of disease activity, 29 because of toxicity, and four for both reasons. Five patients ended study participation or stopped methotrexate for another reason. A higher MTX‐PG3 concentration was associated with a higher rate of methotrexate drug survival (HR 0.86, 95% CI 0.75–0.99), lower FCP (β −3.7, SE 1.3, p < 0.01) and with biochemical response (FCP ≤250 if baseline >250 μg/g; OR 1.1, 95% CI 1.0–1.3). Higher MTX‐PGs were associated with less gastrointestinal intolerance. There was no robust association between MTX‐PGs and HBI or hepatotoxicity. Conclusions: Higher MTX‐PG3 concentrations are related to better methotrexate drug survival and decreased FCP levels. Therefore, MTX‐PG3 could be used for TDM if a target concentration can be established. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Risk factors of work disability in patients with inflammatory bowel disease — A Dutch nationwide web-based survey: Work disability in inflammatory bowel disease

Author

van der Valk, Mirthe E., Mangen, Marie-Josée J., Leenders, Max, Dijkstra, Gerard, van Bodegraven, Ad A., Fidder, Herma H., de Jong, Dirk J., Pierik, Marieke, van der Woude, C. Janneke, Romberg-Camps, Mariëlle J.L., Clemens, Cees H.M., Jansen, Jeroen M., Mahmmod, Nofel, van de Meeberg, Paul C., van der Meulen-de Jong, Andrea E., Ponsioen, Cyriel Y., Bolwerk, Clemens J.M., Vermeijden, J. Reinoud, Siersema, Peter D., van Oijen, Martijn G.H., and Oldenburg, Bas

Published
2014
Full Text
View/download PDF

18. Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies

Author

Severs, Mirjam, Spekhorst, Lieke M, Mangen, Marie-Josée J, Dijkstra, Gerard, Löwenberg, Mark, Hoentjen, Frank, van der Meulen-de Jong, Andrea E, Pierik, Marieke, Ponsioen, Cyriel Y, Bouma, Gerd, van der Woude, Janneke C, van der Valk, Mirthe E, Romberg-Camps, Marielle J L, Clemens, Cees H M, van de Meeberg, Paul, Mahmmod, Nofel, Jansen, Jeroen, Jharap, Bindia, Weersma, Rinse K, Oldenburg, Bas, Festen, Eleonora A M, and Fidder, Herma H

Published
2018
Full Text
View/download PDF

19. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease

Author

Severs, Mirjam, Mangen, Marie-Josée J., Fidder, Herma H., van der Valk, Mirthe E., van der Have, Mike, van Bodegraven, Ad A., Clemens, Cees H. M., Dijkstra, Gerard, Jansen, Jeroen M., de Jong, Dirk J., Mahmmod, Nofel, van de Meeberg, Paul C., van der Meulen-de Jong, Andrea E., Pierik, Marieke, Ponsioen, Cyriel Y., Romberg-Camps, Marielle J. L., Siersema, Peter D., Jharap, Bindia, van der Woude, Janneke C., Zuithoff, Nicolaas P. A., and Oldenburg, Bas

Published
2017
Full Text
View/download PDF

20. 721: IMMUNOMODULATOR WITHDRAWAL FROM ANTI-TNF THERAPY IS NOT ASSOCIATED WITH LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE

Author

Mahmoud, Remi, primary, Schultheiss, Johannes P., additional, Louwers, Jonas M., additional, Kaaij, Michiel T. van der, additional, Hellemondt, Boris P. van, additional, Mahmmod, Nofel, additional, Boeckel, Petra G. van, additional, Jharap, Bindia, additional, Fidder, Herma H., additional, and Oldenburg, Bas, additional

Published
2022
Full Text
View/download PDF

21. Tu1498: WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY

Author

Savelkoul, Edo, primary, Mahmoud, Remi, additional, Jong, Dirk J. De, additional, Dop, Willemijn A. van, additional, Romkens, Tessa E.H, additional, Nissen, Loes H., additional, Mahmmod, Nofel, additional, Boeckel, Petra G. van, additional, Lutgens, Maurice, additional, Mares, Wout, additional, Epping, Ludger, additional, Minderhoud, Itta M., additional, Jansen, Jeroen M., additional, Gisbertz, Ingrid A., additional, Boekema, Paul, additional, Koning, Daan de, additional, Horje, Carmen S. Horjus Talabur, additional, Jharap, Bindia, additional, Oldenburg, Bas, additional, and Hoentjen, Frank, additional

Published
2022
Full Text
View/download PDF

22. Mo1539: ANTI-TNF WITHDRAWAL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN ENDOSCOPIC REMISSION: A PROSPECTIVE STUDY

Author

Mahmoud, Remi, primary, Savelkoul, Edo, additional, Mares, Wout, additional, Goetgebuer, Rogier, additional, Witteman, Ben, additional, Koning, Daan de, additional, Minderhoud, Itta M., additional, Tuyl, Sebastiaan van, additional, Boeckel, Petra G. van, additional, Mahmmod, Nofel, additional, Lutgens, Maurice, additional, Horje, Carmen S. Horjus Talabur, additional, Romkens, Tessa E.H, additional, Akol-Simsek, Dilek, additional, Jansen, Jeroen M., additional, Colombel, Jean Frederic, additional, Hoentjen, Frank, additional, Jharap, Bindia, additional, and Oldenburg, Bas, additional

Published
2022
Full Text
View/download PDF

25. Loss of response to anti-TNF alpha agents depends on treatment duration in patients with inflammatory bowel disease

Author

MS MDL 1, Unit Opleiding MDL, Infection & Immunity, Cancer, Schultheiss, Johannes P D, Mahmoud, Remi, Louwers, Jonas M, van der Kaaij, Michiel T, van Hellemondt, Boris P, van Boeckel, Petra G, Mahmmod, Nofel, Jharap, Bindia, Fidder, Herma H, Oldenburg, Bas, MS MDL 1, Unit Opleiding MDL, Infection & Immunity, Cancer, Schultheiss, Johannes P D, Mahmoud, Remi, Louwers, Jonas M, van der Kaaij, Michiel T, van Hellemondt, Boris P, van Boeckel, Petra G, Mahmmod, Nofel, Jharap, Bindia, Fidder, Herma H, and Oldenburg, Bas

Published
2021

26. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease

Author

Arts-assistenten Kinderen, MS MDL 1, Infection & Immunity, Cancer, Mahmmod, Shaden, Schultheiss, Johannes P D, van Bodegraven, Ad A, Dijkstra, Gerard, Gilissen, Lennard P L, Hoentjen, Frank, Lutgens, Maurice W M D, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Smits, Lisa J T, Tan, Adriaan C I T L, Oldenburg, Bas, Fidder, Herma H, Arts-assistenten Kinderen, MS MDL 1, Infection & Immunity, Cancer, Mahmmod, Shaden, Schultheiss, Johannes P D, van Bodegraven, Ad A, Dijkstra, Gerard, Gilissen, Lennard P L, Hoentjen, Frank, Lutgens, Maurice W M D, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Smits, Lisa J T, Tan, Adriaan C I T L, Oldenburg, Bas, and Fidder, Herma H

Published
2021

28. Healthy Cotwins Share Gut Microbiome Signatures With Their Inflammatory Bowel Disease Twins and Unrelated Patients

Author

Brand, Eelco C., primary, Klaassen, Marjolein A.Y., additional, Gacesa, Ranko, additional, Vich Vila, Arnau, additional, Ghosh, Hiren, additional, de Zoete, Marcel R., additional, Boomsma, Dorret I., additional, Hoentjen, Frank, additional, Horjus Talabur Horje, Carmen S., additional, van de Meeberg, Paul C., additional, Willemsen, Gonneke, additional, Fu, Jingyuan, additional, Wijmenga, Cisca, additional, van Wijk, Femke, additional, Zhernakova, Alexandra, additional, Oldenburg, Bas, additional, Weersma, Rinse K., additional, Brand, Eelco C., additional, Honkoop, Pieter, additional, Jacobs, Rutger J., additional, Ponsioen, Cyriel Y., additional, de Boer, Nanne K.H., additional, Alderlieste, Yasser A., additional, van Herwaarden, Margot A., additional, van Tuyl, Sebastiaan A.C., additional, Lutgens, Maurice W., additional, Janneke van der Woude, C., additional, Mares, Wout G.M., additional, de Koning, Daan B., additional, Bosman, Joukje H., additional, Vecht, Juda, additional, de Schryver, Anneke M.P., additional, van der Meulen-de Jong, Andrea E., additional, Pierik, Marieke J., additional, Boekema, Paul J., additional, Verburg, Robert J., additional, Jharap, Bindia, additional, Jansen, Jeroen M., additional, Stokkers, Pieter C.F., additional, Quispel, Rutger, additional, Mahmmod, Nofel, additional, West, Rachel L., additional, Willems, Marleen, additional, Minderhoud, Itta M., additional, Fidder, Herma H., additional, van Schaik, Fiona D.M., additional, Hirdes, Meike M.C., additional, Boontje, Nynke A., additional, Müskens, Bart L.M., additional, and Romberg-Camps, Marielle J.L., additional

Published
2021
Full Text
View/download PDF

29. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

Author

van der Valk, Mirthe Emilie, Mangen, Marie-Josée J, Leenders, Max, Dijkstra, Gerard, van Bodegraven, Ad A, Fidder, Herma H, de Jong, Dirk J, Pierik, Marieke, van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees HM, Jansen, Jeroen M, Mahmmod, Nofel, van de Meeberg, Paul C, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, Bolwerk, Clemens JM, Vermeijden, J Reinoud, Siersema, Peter D, van Oijen, Martijn GH, and Oldenburg, Bas

Published
2014
Full Text
View/download PDF

30. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease

Author

Mahmmod, Shaden, primary, Schultheiss, Johannes P D, additional, van Bodegraven, Ad A, additional, Dijkstra, Gerard, additional, Gilissen, Lennard P L, additional, Hoentjen, Frank, additional, Lutgens, Maurice W M D, additional, Mahmmod, Nofel, additional, van der Meulen–de Jong, Andrea E, additional, Smits, Lisa J T, additional, Tan, Adriaan C I T L, additional, Oldenburg, Bas, additional, and Fidder, Herma H, additional

Published
2021
Full Text
View/download PDF

31. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study

Author

Derikx, Lauranne A A P, primary, Lantinga, Marten A, additional, de Jong, Dirk J, additional, van Dop, Willemijn A, additional, Creemers, Rob H, additional, Römkens, Tessa E H, additional, Jansen, Jeroen M, additional, Mahmmod, Nofel, additional, West, Rachel L, additional, Tan, Adriaan C I T L, additional, Bodelier, Alexander G L, additional, Gorter, Moniek H P, additional, Boekema, Paul J, additional, Halet, Eric R C, additional, Horjus, Carmen S, additional, van Dijk, Maarten A, additional, Hirdes, Meike M C, additional, Epping Stippel, Ludger S M, additional, Jharap, Bindia, additional, Lutgens, Maurice W M D, additional, Russel, Maurice G, additional, Gilissen, Lennard P L, additional, Nauta, Sjoukje, additional, van Bodegraven, Adriaan A, additional, and Hoentjen, Frank, additional

Published
2020
Full Text
View/download PDF

32. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life

Author

Kanis, Shannon Linda, primary, Modderman, Sanne, additional, Escher, Johanna C, additional, Erler, Nicole, additional, Beukers, Ruud, additional, de Boer, Nanne, additional, Bodelier, Alexander, additional, Depla, Annekatrien C T.M, additional, Dijkstra, Gerard, additional, van Dijk, Anne-Baue Ruth Margaretha, additional, Gilissen, Lennard, additional, Hoentjen, Frank, additional, Jansen, Jeroen M, additional, Kuyvenhoven, Johan, additional, Mahmmod, Nofel, additional, Mallant-Hent, Rosalie C, additional, van der Meulen-de Jong, Andrea E, additional, Noruzi, Anahita, additional, Oldenburg, Bas, additional, Oostenbrug, Liekele E, additional, Ter Borg, Pieter C.J., additional, Pierik, Marieke, additional, Romberg- Camps, Mariëlle, additional, Thijs, Willem, additional, West, Rachel, additional, de Lima, Alison, additional, and van der Woude, C Janneke, additional

Published
2020
Full Text
View/download PDF

33. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial

Author

Stevens, Toer W, primary, Haasnoot, Maria L, additional, D'Haens, Geert R, additional, Buskens, Christianne J, additional, de Groof, E Joline, additional, Eshuis, Emma J, additional, Gardenbroek, Tjibbe J, additional, Mol, Bregje, additional, Stokkers, Pieter C F, additional, Bemelman, Willem A, additional, Ponsioen, Cyriel Y, additional, Hart, Ailsa, additional, Warusavitarne, Janindra, additional, Van Bodegraven, Ad A., additional, Brink, Menno A., additional, Consten, Esther C.J., additional, Van Wagensveld, Bart A., additional, Rijk, Marno C.M., additional, Crolla, Rogier M.P.H., additional, Noomen, Casper G., additional, Houdijk, Alexander P.J., additional, Mallant, Rosalie C., additional, Boom, Maarten, additional, Marsman, Willem A., additional, Stockmann, Hein B., additional, De Groof, A. Jeroen, additional, Bruin, Karlien, additional, Maring, John, additional, van Ditzhuijsen, Theo, additional, Prins, Hubert, additional, van den Brande, Jan, additional, Kingma, Paul, additional, van Geloven, Anna, additional, de Boer, Nanne, additional, van der Peet, Donald, additional, Jansen, Jeroen, additional, Gerhards, Michael, additional, van der Woude, Janneke, additional, Schouten, Ruud, additional, Oldenburg, Bas, additional, van Hillegersberg, Richard, additional, West, Rachel, additional, Mannaerts, Guido, additional, Spanier, Marcel, additional, Spillenaar Bilgen, Ernst Jan, additional, Lieverse, Rob, additional, van der Zaag, Edwin, additional, Depla, Annekatrien, additional, van de Laar, Arnold, additional, Bolwerk, Clemens, additional, Brouwer, Hans, additional, Mahmmod, Nofel, additional, Hazebroek, Eric, additional, Vecht, Juda, additional, Pierik, Robert, additional, Dijkstra, Gerard, additional, Hofker, Sijbrand, additional, Uiterwaal, Tessa, additional, Eijsbouts, Quirijn, additional, Oostenbrug, Liekele, additional, Sosef, Meindert, additional, Cahen, Djuna, additional, van der Werff, Sjoerd, additional, Marinelli, Andreas, additional, Peters, Job, additional, Cense, Huib, additional, Talstra, Nynke, additional, and Morar, Pritesh, additional

Published
2020
Full Text
View/download PDF

34. Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events

Author

Zorgeenheid Traumatologie, MS MDL 1, Infection & Immunity, Cancer, Asscher, Vera E R, van der Vliet, Quirine, van der Aalst, Karen, van der Aalst, Anniek, Brand, Eelco C, van der Meulen-de Jong, Andrea E, Oldenburg, Bas, Pierik, Marieke J, van Tuyl, Bas, Mahmmod, Nofel, Maljaars, P W Jeroen, Fidder, Herma H, Dutch ICC, Zorgeenheid Traumatologie, MS MDL 1, Infection & Immunity, Cancer, Asscher, Vera E R, van der Vliet, Quirine, van der Aalst, Karen, van der Aalst, Anniek, Brand, Eelco C, van der Meulen-de Jong, Andrea E, Oldenburg, Bas, Pierik, Marieke J, van Tuyl, Bas, Mahmmod, Nofel, Maljaars, P W Jeroen, Fidder, Herma H, and Dutch ICC

Published
2020

35. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.

Author

Kanis, Shannon Linda, Modderman, Sanne, Escher, Johanna C., Erler, Nicole, Beukers, Ruud, de Boer, Nanne, Bodelier, Alexander, Depla, Annekatrien C. T. M., Dijkstra, Gerard, van Dijk, Anne-Baue Ruth Margaretha, Gilissen, Lennard, Hoentjen, Frank, Jansen, Jeroen M., Kuyvenhoven, Johan, Mahmmod, Nofel, Mallant-Hent, Rosalie C., van der Meulen-de, Andrea E., Noruzi, Anahita, Oldenburg, Bas, and Oostenbrug, Liekele E.

Subjects
INFLAMMATORY bowel diseases, MOTHER-child relationship, IMMUNIZATION of children, TYPE 1 diabetes, SMALL for gestational age, LOW birth weight, PEDIATRIC gastroenterology
Published
2021
Full Text
View/download PDF

36. Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis : results of a 15-year multicentre, multinational cohort study

Author

Ten Hove, Joren R, Shah, Shailja C, Shaffer, Seth R, Bernstein, Charles N, Castaneda, Daniel, Palmela, Carolina, Mooiweer, Erik, Elman, Jordan, Kumar, Akash, Glass, Jason, Axelrad, Jordan, Ullman, Thomas A, Colombel, Jean-Frederic, Torres, Joana, van Bodegraven, Adriaan A, Hoentjen, Frank, Jansen, Jeroen M, de Jong, Michiel E, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, van der Woude, Christine J, Itzkowitz, Steven H, Oldenburg, Bas, Ten Hove, Joren R, Shah, Shailja C, Shaffer, Seth R, Bernstein, Charles N, Castaneda, Daniel, Palmela, Carolina, Mooiweer, Erik, Elman, Jordan, Kumar, Akash, Glass, Jason, Axelrad, Jordan, Ullman, Thomas A, Colombel, Jean-Frederic, Torres, Joana, van Bodegraven, Adriaan A, Hoentjen, Frank, Jansen, Jeroen M, de Jong, Michiel E, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, van der Woude, Christine J, Itzkowitz, Steven H, and Oldenburg, Bas

Published
2019

37. Malignant and Nonmalignant Complications of the Rectal Stump in Patients with Inflammatory Bowel Disease

Author

MS MDL 1, Pathologie Pathologen staf, MS CGO, Infection & Immunity, Ten Hove, Joren R, Bogaerts, Jonathan M K, Bak, Michiel T J, Laclé, Miangela M, Meij, Vincent, Derikx, Lauranne A A P, Hoentjen, Frank, Mahmmod, Nofel, van Tuyl, Sebastiaan A, Oldenburg, Bas, MS MDL 1, Pathologie Pathologen staf, MS CGO, Infection & Immunity, Ten Hove, Joren R, Bogaerts, Jonathan M K, Bak, Michiel T J, Laclé, Miangela M, Meij, Vincent, Derikx, Lauranne A A P, Hoentjen, Frank, Mahmmod, Nofel, van Tuyl, Sebastiaan A, and Oldenburg, Bas

Published
2019

38. Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study

Author

MS MDL 1, Cancer, Infection & Immunity, Ten Hove, Joren R, Shah, Shailja C, Shaffer, Seth R, Bernstein, Charles N, Castaneda, Daniel, Palmela, Carolina, Mooiweer, Erik, Elman, Jordan, Kumar, Akash, Glass, Jason, Axelrad, Jordan, Ullman, Thomas A, Colombel, Jean-Frederic, Torres, Joana, van Bodegraven, Adriaan A, Hoentjen, Frank, Jansen, Jeroen M, de Jong, Michiel E, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, van der Woude, Christine J, Itzkowitz, Steven H, Oldenburg, Bas, MS MDL 1, Cancer, Infection & Immunity, Ten Hove, Joren R, Shah, Shailja C, Shaffer, Seth R, Bernstein, Charles N, Castaneda, Daniel, Palmela, Carolina, Mooiweer, Erik, Elman, Jordan, Kumar, Akash, Glass, Jason, Axelrad, Jordan, Ullman, Thomas A, Colombel, Jean-Frederic, Torres, Joana, van Bodegraven, Adriaan A, Hoentjen, Frank, Jansen, Jeroen M, de Jong, Michiel E, Mahmmod, Nofel, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, van der Woude, Christine J, Itzkowitz, Steven H, and Oldenburg, Bas

Published
2019

39. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.

Author

Derikx, Lauranne A A P, Lantinga, Marten A, Jong, Dirk J de, Dop, Willemijn A van, Creemers, Rob H, Römkens, Tessa E H, Jansen, Jeroen M, Mahmmod, Nofel, West, Rachel L, Tan, Adriaan C I T L, Bodelier, Alexander G L, Gorter, Moniek H P, Boekema, Paul J, Halet, Eric R C, Horjus, Carmen S, Dijk, Maarten A van, Hirdes, Meike M C, Stippel, Ludger S M Epping, Jharap, Bindia, and Lutgens, Maurice W M D

Abstract

Background and Aims The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of COVID-19 in IBD patients. Second, we determined COVID-19 incidences in IBD patients and compared this with the general population. Methods We conducted a multicentre, nationwide IBD cohort study in The Netherlands and identified patients with COVID-19. First, we assessed the COVID-19 disease course and outcomes. Second, we compared COVID-19 incidences between our IBD study cohort and the general Dutch population. Results We established an IBD cohort of 34 763 patients. COVID-19 was diagnosed in 100/34 763 patients [0.29%]; 20/100 of these patients [20%] had severe COVID-19 defined as admission to the intensive care unit, mechanical ventilation, and/or death. Hospitalisation occurred in 59/100 [59.0%] patients and 13/100 [13.0%] died. All patients who died had comorbidities and all but one were ≥65 years old. In line, we identified ≥1 comorbidity as an independent risk factor for hospitalisation (odds ratio [OR] 4.20, 95% confidence interval [CI] 1.58–11.17,; p = 0.004). Incidences of COVID-19 between the IBD study cohort and the general population were comparable (287.6 [95% CI 236.6–349.7] versus 333.0 [95% CI 329.3–336.7] per 100000 patients, respectively; p = 0.15). Conclusions Of 100 cases with IBD and COVID-19, 20% developed severe COVID-19, 59% were hospitalised and 13% died. A comparable COVID-19 risk was found between the IBD cohort [100/34 763 = 0.29%] and the general Dutch population. The presence of ≥1 comorbidities was an independent risk factor for hospitalisation due to COVID-19. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events.

Author

Asscher, Vera E. R., van der Vliet, Quirine, van der Aalst, Karen, van der Aalst, Anniek, Brand, Eelco C., van der Meulen-de Jong, Andrea E., Oldenburg, Bas, Pierik, Marieke J., van Tuyl, Bas, Mahmmod, Nofel, Maljaars, P. W. Jeroen, and Fidder, Herma H.

Subjects
INFLAMMATORY bowel diseases, OLDER patients, CROHN'S disease, NECROSIS, COMORBIDITY
Abstract

Purpose: To assess safety and effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in IBD patients ≥ 60 years. Methods: Ninety IBD patients ≥ 60 years at initiation of anti-TNF therapy, 145 IBD patients ≥ 60 years without anti-TNF therapy and 257 IBD patients < 60 years at initiation of anti-TNF therapy were retrospectively included in this multicentre study. Primary outcome was the occurrence of severe adverse events (SAEs), serious infections and malignancies. Secondary outcome was effectiveness of therapy. Cox regression analyses were used to assess differences in safety and effectiveness. In safety analyses, first older patients with and without anti-TNF therapy and then older and younger patients with anti-TNF therapy were assessed. Results: In older IBD patients, the use of anti-TNF therapy was associated with serious infections (aHR 3.920, 95% CI 1.185–12.973, p =.025). In anti-TNF-exposed patients, cardiovascular disease associated with serious infections (aHR 3.279, 95% CI 1.098–9.790, p =.033) and the presence of multiple comorbidities (aHR 9.138 (1.248–66.935), p =.029) with malignancies, while patient age did not associate with safety outcomes. Effectiveness of therapy was not affected by age or comorbidity. Conclusion: Older patients receiving anti-TNF therapy have a higher risk of serious infections compared with older IBD patients without anti-TNF therapy, but not compared with younger patients receiving anti-TNF therapy. However, in anti-TNF-exposed patients, comorbidity was found to be an indicator with regards to SAEs. Effectiveness was comparable between older and younger patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

41. Novel Perceived Stress and Life Events Precede Flares of Inflammatory Bowel Disease: A Prospective 12-Month Follow-Up Study

Author

Wintjens, Dion S J, primary, de Jong, Marin J, additional, van der Meulen-de Jong, Andrea E, additional, Romberg-Camps, Mariëlle J, additional, Becx, Marco C, additional, Maljaars, Jeroen P, additional, van Bodegraven, Ad A, additional, Mahmmod, Nofel, additional, Markus, Tineke, additional, Haans, Jeoffrey, additional, Masclee, Ad A M, additional, Winkens, Bjorn, additional, Jonkers, Daisy M A E, additional, and Pierik, Marie J, additional

Published
2018
Full Text
View/download PDF

43. Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study

Author

ten Hove, Joren R, primary, Shah, Shailja C, additional, Shaffer, Seth R, additional, Bernstein, Charles N, additional, Castaneda, Daniel, additional, Palmela, Carolina, additional, Mooiweer, Erik, additional, Elman, Jordan, additional, Kumar, Akash, additional, Glass, Jason, additional, Axelrad, Jordan, additional, Ullman, Thomas A, additional, Colombel, Jean-Frederic, additional, Torres, Joana, additional, van Bodegraven, Adriaan A, additional, Hoentjen, Frank, additional, Jansen, Jeroen M, additional, de Jong, Michiel E, additional, Mahmmod, Nofel, additional, van der Meulen-de Jong, Andrea E, additional, Ponsioen, Cyriel Y, additional, van der Woude, Christine J, additional, Itzkowitz, Steven H, additional, and Oldenburg, Bas, additional

Published
2018
Full Text
View/download PDF

44. 604 - Consecutive Negative Findings on Colonoscopy During Surveillance Predict a Low Risk of Advanced Neoplasia in Patients with Longstanding Colitis: Results of a 15-Year Multicenter, Multinational Cohort Study

Author

Shah, Shailja, primary, Ten Hove, Joren, additional, Shaffer, Seth, additional, Bernstein, Charles N., additional, Castaneda, Daniel, additional, Palmela, Carolina, additional, Mooiweer, Erik, additional, Elman, Jordan, additional, Kumar, Akash, additional, Axelrad, Jordan, additional, Glass, Jason, additional, Ullman, Thomas A., additional, Colombel, Jean Frederic, additional, Torres, Joana, additional, van Bodegraven, Adriaan A., additional, Hoentjen, Frank, additional, Jansen, Jeroen, additional, de Jong, Michiel E., additional, Mahmmod, Nofel, additional, Van Der Meulen, Andrea, additional, Ponsioen, Cyriel, additional, Van Der Woude, Christien Janneke, additional, Itzkowitz, Steven, additional, and Oldenburg, Bas, additional

Published
2018
Full Text
View/download PDF

45. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy

Author

Van Der Valk, Mirthe Emilie, Mangen, Marie Josée J, Leenders, Max, Dijkstra, Gerard, Van Bodegraven, Ad A., Fidder, Herma H., De Jong, Dirk J., Pierik, Marieke, Van Der Woude, C. Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees H M, Jansen, J.M., Mahmmod, Nofel, Van De Meeberg, Paul C., Van Der Meulen-De Jong, Andrea E., Ponsioen, Cyriel Y., Bolwerk, Clemens J M, Vermeijden, J. Reinoud, Siersema, Peter D., Van Oijen, Martijn G H, Oldenburg, Bas, LS IRAS EEPI GRA (Gezh.risico-analyse), IRAS RATIA-SIB, Risk Assessment of Toxic and Immunomodulatory Agents, LS IRAS EEPI GRA (Gezh.risico-analyse), IRAS RATIA-SIB, Risk Assessment of Toxic and Immunomodulatory Agents, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Translational Immunology Groningen (TRIGR), Groningen Institute for Organ Transplantation (GIOT), Interne Geneeskunde, Health promotion, RS: NUTRIM - R2 - Gut-liver homeostasis, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Oncology, Gastroenterology and hepatology, CCA - Quality of life, and Gastroenterology & Hepatology

Subjects
Male, Total cost, Anti-Inflammatory Agents, Crohn's Disease, Inflammatory bowel disease, Quality of life, Cost of Illness, Crohn Disease, QUALITY-OF-LIFE, Surveys and Questionnaires, Epidemiology, Absenteeism, Outpatient clinic, EPIDEMIOLOGY, health care economics and organizations, Netherlands, Aged, 80 and over, Crohn's disease, Gastroenterology, Antibodies, Monoclonal, Health Care Costs, Middle Aged, Ulcerative colitis, WORK PRODUCTIVITY, CROHNS-DISEASE, Hospitalization, ULCERATIVE-COLITIS, Sick leave, Female, Sick Leave, BURDEN, Adult, medicine.medical_specialty, Adolescent, ORTHOPEDIC-SURGERY, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], ILLNESS, Antibodies, Monoclonal, Humanized, Young Adult, medicine, Humans, Ulcerative Colitis, Aged, business.industry, Inflammatory Bowel Disease, Adalimumab, medicine.disease, Infliximab, EVOLUTION, Surgery, RHEUMATOID-ARTHRITIS, Logistic Models, Multivariate Analysis, Colitis, Ulcerative, Health Expenditures, business, Economic Evaluation, Follow-Up Studies
Abstract

Item does not contain fulltext OBJECTIVE: The introduction of anti tumour necrosis factor-alpha (anti-TNFalpha) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) following the introduction of these drugs. We aimed to assess the healthcare costs and productivity losses in a large cohort of IBD patients. DESIGN: Crohn's disease (CD) and ulcerative colitis (UC) patients from seven university hospitals and seven general hospitals were invited to fill-out a web-based questionnaire. Cost items were derived from a 3 month follow-up questionnaire and categorised in outpatient clinic, diagnostics, medication, surgery and hospitalisation. Productivity losses included sick leave of paid and unpaid work. Costs were expressed as mean 3-month costs per patients with a 95% CI obtained using non-parametric bootstrapping. RESULTS: A total of 1315 CD patients and 937 UC patients were included. Healthcare costs were almost three times higher in CD as compared with UC, euro1625 (95% CI euro1476 to euro1775) versus euro595 (95% CI euro505 to euro685), respectively (p

Published
2014
Full Text
View/download PDF

46. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial

Author

Ponsioen, Cyriel Y, primary, de Groof, E Joline, additional, Eshuis, Emma J, additional, Gardenbroek, Tjibbe J, additional, Bossuyt, Patrick M M, additional, Hart, Ailsa, additional, Warusavitarne, Janindra, additional, Buskens, Christianne J, additional, van Bodegraven, Ad A, additional, Brink, Menno A, additional, Consten, Esther C J, additional, van Wagensveld, Bart A, additional, Rijk, Marno C M, additional, Crolla, Rogier M P H, additional, Noomen, Casper G, additional, Houdijk, Alexander P J, additional, Mallant, Rosalie C, additional, Boom, Maarten, additional, Marsman, Willem A, additional, Stockmann, Hein B, additional, Mol, Bregje, additional, de Groof, A Jeroen, additional, Stokkers, Pieter C, additional, D'Haens, Geert R, additional, Bemelman, Willem A, additional, Bruin, Karlien, additional, Maring, John, additional, van Ditzhuijsen, Theo, additional, Prins, Hubert, additional, van den Brande, Jan, additional, Kingma, Paul, additional, van Geloven, Anna, additional, de Boer, Nanne, additional, van der Peet, Donald, additional, Jansen, Jeroen, additional, Gerhards, Michael, additional, van der Woude, Janneke, additional, Schouten, Ruud, additional, Oldenburg, Bas, additional, van Hillegersberg, Richard, additional, West, Rachel, additional, Mannaerts, Guido, additional, Spanier, Marcel, additional, Spillenaar Bilgen, Ernst Jan, additional, Lieverse, Rob, additional, van der Zaag, Edwin, additional, Depla, Annekatrien, additional, van de Laar, Arnold, additional, Bolwerk, Clemens, additional, Brouwer, Hans, additional, Mahmmod, Nofel, additional, Hazebroek, Eric, additional, Vecht, Juda, additional, Pierik, Robert, additional, Dijkstra, Gerard, additional, Hofker, Sijbrand, additional, Uiterwaal, Tessa, additional, Eijsbouts, Quirijn, additional, Oostenbrug, Liekele, additional, Sosef, Meindert, additional, Cahen, Djuna, additional, van der Werff, Sjoerd, additional, Marinelli, Andreas, additional, Peters, Job, additional, Cense, Huib, additional, Talstra, Nynke, additional, and Morar, Pritesh, additional

Published
2017
Full Text
View/download PDF

47. Telemedicine Enables a Safe Shift from Examination Room Based Care to Personalized Care for Inflammatory Bowel Disease: A Pragmatic Randomized Multicenter Trial With Myibdcoach

Author

de Jong, Marin, primary, Van Der Meulen, Andrea, additional, Romberg-Camps, Marielle, additional, Becx, Marco, additional, Cilissen, Mia, additional, Maljaars, Jeroen, additional, van Bodegraven, Ad, additional, Mahmmod, Nofel, additional, Markus-de Kwaadsteniet, M.L., additional, Hameeteman, Wim, additional, Dijkstra, Gerard, additional, Masclee, Ad, additional, Boonen, Annelies, additional, Jonkers, Daisy, additional, van Tubergen, Astrid, additional, and Pierik, Marie, additional

Published
2017
Full Text
View/download PDF

48. Novel Perceived Stress and Life Events Precede Flares of Inflammatory Bowel Disease: A Prospective 12-Month Follow-Up Study.

Author

Wintjens, Dion S J, Jong, Marin J de, Jong, Andrea E van der Meulen-de, Romberg-Camps, Mariëlle J, Becx, Marco C, Maljaars, Jeroen P, Bodegraven, Ad A van, Mahmmod, Nofel, Markus, Tineke, Haans, Jeoffrey, Masclee, Ad A M, Winkens, Bjorn, Jonkers, Daisy M A E, and Pierik, Marie J

Abstract

Background and Aims Inflammatory bowel disease [IBD] is characterized by recurrent disease flares. The impact of psychosocial wellbeing on the occurrence of flares is unclear. In this prospective study, we aimed to evaluate the association between patient-reported psychosocial wellbeing and disease flares using continuous monitoring. Methods Consecutive IBD patients were recruited from the myIBDcoach telemedicine study cohort. Over 12 months, participants reported on disease activity together with anxiety, depression, fatigue, perceived stress and life events every 1–3 months. Flares were defined using a combination of clinical disease activity and additional measurements. Generalized estimating equation models were used to assess associations between psychosocial wellbeing and flares over time. The influences of both the presence of psychosocial symptoms in general as well as novel psychosocial symptoms were analysed. Results In total, 417 patients were included. Forty-nine patients [11.8%] experienced a flare during the study period. The occurrence of life events in the preceding 3 months was positively associated with flares (odds ratio [OR] = 1.81; 95% confidence interval [CI] = 1.04–3.17), while the presence of anxiety, depression, fatigue and perceived stress in general was not. However, novel perceived stress [OR = 2.92; 95% CI = 1.44–5.90] was associated with flares. Conclusions The occurrence of life events and novel perceived stress are associated with disease flares in the next 3 months, while the presence of perceived stress in general is not. These findings underline the importance of continuous personalized monitoring of IBD patients and may contribute to the prevention of disease flares. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

49. Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study.

Author

ten Hove, Joren R., Shah, Shailja C., Shaffer, Seth R., Bernstein, Charles N., Castaneda, Daniel, Palmela, Carolina, Mooiweer, Erik, Elman, Jordan, Kumar, Akash, Glass, Jason, Axelrad, Jordan, Ullman, Thomas A., Colombel, Jean-Frederic, Torres, Joana, van Bodegraven, Adriaan A., Hoentjen, Frank, Jansen, Jeroen M., de Jong, Michiel E., Mahmmod, Nofel, and van der Meulen-de Jong, Andrea E.

Subjects
ADENOMATOUS polyps, BOWEL preparation (Procedure), INFLAMMATORY bowel diseases
Published
2019
Full Text
View/download PDF

50. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease

Author

UMC Utrecht, Unit Opleiding Aios, Cancer, HEE, MS MDL 1, Infection & Immunity, Arts Assistenten Longziekten, Biostatistiek Onderzoek, Other research (not in main researchprogram), Severs, Mirjam, Mangen, Marie Josée J., Fidder, Herma H., Van Der Valk, Mirthe E., Van Der Have, Mike, Van Bodegraven, Ad A., Clemens, Cees H M, Dijkstra, Gerard, Jansen, Jeroen M., de Jong, Dirk J, Mahmmod, Nofel, van de Meeberg, Paul C, Van der Meulen-de Jong, Andrea E, Pierik, Marieke, Ponsioen, Cyriel Y, Romberg-Camps, Marielle J.L., Siersema, Peter D., Jharap, Bindia, van der Woude, C Janneke, Zuithoff, Nicolaas P.A., Oldenburg, Bas, UMC Utrecht, Unit Opleiding Aios, Cancer, HEE, MS MDL 1, Infection & Immunity, Arts Assistenten Longziekten, Biostatistiek Onderzoek, Other research (not in main researchprogram), Severs, Mirjam, Mangen, Marie Josée J., Fidder, Herma H., Van Der Valk, Mirthe E., Van Der Have, Mike, Van Bodegraven, Ad A., Clemens, Cees H M, Dijkstra, Gerard, Jansen, Jeroen M., de Jong, Dirk J, Mahmmod, Nofel, van de Meeberg, Paul C, Van der Meulen-de Jong, Andrea E, Pierik, Marieke, Ponsioen, Cyriel Y, Romberg-Camps, Marielle J.L., Siersema, Peter D., Jharap, Bindia, van der Woude, C Janneke, Zuithoff, Nicolaas P.A., and Oldenburg, Bas

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results